General Information of the Drug (ID: M6APDG03607)
Name
ISIS 6442
Status
Investigative
TTD Drug ID
D07TMI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
PKC-eta messenger RNA (PRKCH mRNA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6442. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6442 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). [1], [2]
References
Ref 1 METTL3-mediated N (6)-methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics. 2022 Jan 1;12(1):277-289. doi: 10.7150/thno.63441. eCollection 2022.
Ref 2 US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.